Molecular advances in plasminogen activator inhibitor 1 interaction with thrombin and tissue-type plasminogen activator

Trends in Cardiovascular Medicine

Volumn 7, Issue 2, 1997, Pages 47-51

  Stoop, Allart ^a   Van Meijer, Marja ^a   Horrevoets, Anton J G ^a   Pannekoek, Hans ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERINE PROTEINASE INHIBITOR; THROMBIN; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; VITRONECTIN;

ATHEROGENESIS; ATHEROSCLEROSIS; ENZYME DEGRADATION; ENZYME INHIBITOR COMPLEX; HUMAN; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFECT; PROTEINASE INHIBITION; REVIEW; VASCULAR SMOOTH MUSCLE;

EID: 0030998624     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(96)00141-7     Document Type: Review

References (22)

1. Björk I, Danielsson A: 1986. Antithrombin and related inhibitors of coagulation proteinases. In Barrett AJ, Salvesen G, eds. Proteinase Inhibitors. Amsterdam, Elsevier, pp 489-513.
2. Carmeliet P, Collen D: 1995. Gene targeting and gene transfer studies of the plasminogen/plasmin system: implications in thrombosis, hemostasis, neointima formation, and atherosclerosis. FASEB J 9:934-938.
3. Carmeliet P, Stassen JM, Schoonjans L, et al.: 1993. Plasminogen activator inhibitor-1 deficient mice. II. Effect on haemostasis, thrombosis, and thrombolysis. J Clin Invest 92:2756-2760.
4. Ehrlich HJ, Klein Gebbink R, Keijer J, Linders M, Preissner KT, Pannekoek H: 1990. Alteration of serpin specificity by a protein cofactor: vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties. J Biol Chem 265:13,029-13,035.
5. Ehrlich HJ, Keijer J, Preissner KT, Klein Gebbink R, Pannekoek H: 1991a. Functional interaction of plasminogen activator inhibitor 1 (PAI-1) and heparin. Biochemistry 30:1012-1028.
6. Ehrlich HJ, Klein Gebbink R, Preissner KT, et al.: 1991b. Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix. J Cell Biol 115:1773-1781.
7. Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D: 1992. Complete deficiency of plasminogen activator inhibitor 1 due to a frame-shift mutation. N Engl J Med 327:1729-1733.
8. Huber R, Carrell RW: 1989. Implications of the three-dimensional structure of α1-antitrypsin for the structure and functions of serpins. Biochemistry 28:8951-8966.
9. Keijer J, Ehrlich HJ, Linders M, Preissner KT, Pannekoek H: 1991a. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator. J Biol Chem 266:10,700-10,707.
10. Keijer J, Linders M, Wegman JJ, Ehrlich HJ, Mertens K, Pannekoek H: 1991b. On the target specificity of plasminogen activator inhibitor 1 (PAI-1): the effect of heparin, vitronectin and the reactive center. Blood 78: 1254-1261.
11. Klein Gebbink R, Reynolds CH, Tollefsen D, Mertens K, Pannekoek H: 1993. Specific glycosaminoglycans support the inhibition of thrombin by plasminogen activator inhibitor 1. Biochemistry 32:1675-1680.
12. Lucore CL, Sobel BE: 1988. Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications. Circulation 77:660-669.
13. Mimuro J, Schleef RR, Loskutoff DJ: 1987. Extracellular matrix of bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood 70:721-728.
14. Nelken NA, Soifer SJ, O'Keefe J, Vu TK, Charo IF, Coughlin SR: 1992. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 90:1614-1621.
15. Noda-Heiny H, Fujii S, Sobel BE: 1993. Induction of vascular smooth muscle cells of plasminogen activator inhibitor-1 by thrombin. Circ Res 72:36-43.
16. 1-Antitrypsin Pittsburgh (358 Met → Arg), a fatal bleeding disorder. N Engl J Med 309:694-698.
17. 1 inhibitor functions as a suicide substrate. Biochem 30:8876-8882.
18. Seiffert D, Wagner NN, Loskutoff DJ: 1990. Serum-derived vitronectin influences the pericellular distribution of type 1 plasminogen activator inhibitor. J Cell Biol 111:1283-1291.
19. Stefansson S, Lawrence DA, Scott Argraves W: 1996. Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2. J Biol Chem 271:8215-8220.
20. Travis J, Salvesen GS: 1983. Human plasma proteinase inhibitors. Annu Rev Biochem 52: 655-709.
21. Wojta J, Gallicchio M, Zoelner H, et al.: 1993. Thrombin stimulates expression of tissue-type plasminogen activator and plasminogen activator inhibitor 1 in cultured human vascular smooth muscle cells. Thromb Haemost 70:469-474.
22. Zheng X, Saunders TL, Camper SA, Samuelson LC, Ginsburg D: 1995. Vitronectin is not essential for normal development and fertility. Proc Natl Acad Sci USA 92:12,426-12,430.